The State State of Lung Cancer Research: A Global Analysis

被引:165
作者
Aggarwal, Ajay [1 ]
Lewison, Grant [1 ,2 ]
Idir, Saliha [3 ]
Peters, Matthew [4 ]
Aldige, Carolyn [5 ]
Boerckel, Win [6 ]
Boyle, Peter [7 ]
Trimble, Edward L. [8 ]
Roe, Philip [2 ]
Sethi, Tariq [9 ]
Fox, Jesme [10 ]
Sullivan, Richard [1 ]
机构
[1] Kings Coll London, Inst Canc Policy, London, England
[2] Evaluametrics Ltd, London, England
[3] Macquarie Univ, Fac Med & Hlth Sci, Sydney, NSW, Australia
[4] Pfizer Int Operat, Oncol Europe Africa & Middle East Business Unit, Paris, France
[5] Prevent Canc Fdn, Alexandria, VA USA
[6] Canc Care, New York, NY USA
[7] Int Prevent Res Inst, Lyon, France
[8] NCI, Ctr Global Hlth, Bethesda, MD 20892 USA
[9] Kings Coll London, Dept Resp Med, London, England
[10] Roy Castle Lung Canc Fdn, Liverpool, Merseyside, England
关键词
Research; Lung cancer; Bibliometrics; Health policy; CLINICAL-TRIALS; STAGE; RADIOTHERAPY; CARE; CHEMOTHERAPY; DIAGNOSIS; MEDIA; BIBLIOMETRICS; MANAGEMENT; SURVIVAL;
D O I
10.1016/j.jtho.2016.03.010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Lung cancer is the leading cause of years of life lost because of cancer and is associated with the highest economic burden relative to other tumor types. Research remains at the cornerstone of achieving improved outcomes of lung cancer. We present the results of a comprehensive analysis of global lung cancer research between 2004 and 2013 (10 years). Methods: The study used bibliometrics to undertake a quantitative analysis of research output in the 24 leading countries in cancer research internationally on the basis of articles and reviews in the Web of Science (WoS) database. Results: A total of 32,161 lung cancer research articles from 2085 different journals were analyzed. Lung cancer research represented only 5.6% of overall cancer research in 2013, a 1.2% increase since 2004. The commitment to lung cancer research has fallen in most countries apart from China and shows no correlation with lung cancer burden. A review of key research types demonstrated that diagnostics, screening, and quality of life research represent 4.3%, 1.8%, and 0.3% of total lung cancer research, respectively. The leading research types were genetics (20%), systemic therapies (17%), and prognostic biomarkers (16%). Research output is increasingly basic science, with a decrease in clinical translational research output during this period. Conclusions: Our findings have established that relative to the huge health, social, and economic burden associated with lung cancer, the level of world research output lags significantly behind that of research on other malignancies. Commitment to diagnostics, screening, and quality of life research is much lower than to basic science and medical research. The study findings are expected to provide the requisite knowledge to guide future cancer research programs in lung cancer. (C) 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc.
引用
收藏
页码:1040 / 1050
页数:11
相关论文
共 47 条
  • [1] The media and cancer: education or entertainment? An ethnographic study of European cancer journalists
    Aggarwal, Ajay
    Batura, Rekha
    Sullivan, Richard
    [J]. ECANCERMEDICALSCIENCE, 2014, 8
  • [2] Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial
    Albain, Kathy S.
    Swann, R. Suzanne
    Rusch, Valerie W.
    Turrisi, Andrew T., III
    Shepherd, Frances A.
    Smith, Colum
    Chen, Yuhchyau
    Livingston, Robert B.
    Feins, Richard H.
    Gandara, David R.
    Fry, Willard A.
    Darling, Gail
    Johnson, David H.
    Green, Mark R.
    Miller, Robert C.
    Ley, Joanne
    Sause, Willliam T.
    Cox, James D.
    [J]. LANCET, 2009, 374 (9687) : 379 - 386
  • [3] American Cancer Society, 2009, GLOB CANC FACTS FIG
  • [4] [Anonymous], 2014, SNAPSH LUNG CANC
  • [5] [Anonymous], 2014, SAV LIV RES ANN REP
  • [6] GENOMIC INSTABILITY IN CANCER Strategies to improve radiotherapy with targeted drugs
    Begg, Adrian C.
    Stewart, Fiona A.
    Vens, Conchita
    [J]. NATURE REVIEWS CANCER, 2011, 11 (04) : 239 - 253
  • [7] Social inequalities in non-small cell lung cancer management and survival: a population-based study in central Sweden
    Berglund, Anders
    Holmberg, Lars
    Tishelman, Carol
    Wagenius, Gunnar
    Eaker, Sonja
    Lambe, Mats
    [J]. THORAX, 2010, 65 (04) : 327 - 333
  • [8] Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study
    Bradley, Jeffrey D.
    Paulus, Rebecca
    Komaki, Ritsuko
    Masters, Gregory
    Blumenschein, George
    Schild, Steven
    Bogart, Jeffrey
    Hu, Chen
    Forster, Kenneth
    Magliocco, Anthony
    Kavadi, Vivek
    Garces, Yolanda I.
    Narayan, Samir
    Iyengar, Puneeth
    Robinson, Cliff
    Wynn, Raymond B.
    Koprowski, Christopher
    Meng, Joanne
    Beitler, Jonathan
    Gaur, Rakesh
    Curran, Walter, Jr.
    Choy, Hak
    [J]. LANCET ONCOLOGY, 2015, 16 (02) : 187 - 199
  • [9] Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population
    Brzezianska, Ewa
    Karbownik, Malgorzata
    Migdalska-Sek, Monika
    Pastuszak-Lewandoska, Dorota
    Wloch, Jan
    Lewinski, Andrzej
    [J]. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2006, 599 (1-2) : 26 - 35
  • [10] Evidence-informed frameworks for cost-effective cancer care and prevention in low, middle, and high-income countries
    Chalkidou, Kalipso
    Marquez, Patricio
    Dhillon, Preet K.
    Teerawattananon, Yot
    Anothaisintawee, Thunyarat
    Gadelha, Carlos Augusto Grabois
    Sullivan, Richard
    [J]. LANCET ONCOLOGY, 2014, 15 (03) : E119 - E131